IL191426A - Erythropoietin polypeptides, their preparation and uses thereof - Google Patents

Info

Publication number

IL191426A

IL191426A IL191426A IL19142608A IL191426A IL 191426 A IL191426 A IL 191426A IL 191426 A IL191426 A IL 191426A IL 19142608 A IL19142608 A IL 19142608A IL 191426 A IL191426 A IL 191426A

Authority

IL

Israel

Prior art keywords

polypeptide

amino acids

seq

variant

epo

Prior art date

2005-11-24

Links

• Espacenet
• Global Dossier
• Discuss

• 108090000394 Erythropoietin Proteins 0.000 title claims description 215
• 102000003951 Erythropoietin Human genes 0.000 title claims description 206
• 238000002360 preparation method Methods 0.000 title description 13
• 108090000765 processed proteins & peptides Proteins 0.000 claims description 528
• 102000004196 processed proteins & peptides Human genes 0.000 claims description 516
• 229920001184 polypeptide Polymers 0.000 claims description 507
• 150000001413 amino acids Chemical class 0.000 claims description 409
• OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 claims description 134
• 229940105423 erythropoietin Drugs 0.000 claims description 114
• 125000003275 alpha amino acid group Chemical group 0.000 claims description 107
• 210000004027 cell Anatomy 0.000 claims description 107
• 108090000623 proteins and genes Proteins 0.000 claims description 101
• 241000282414 Homo sapiens Species 0.000 claims description 90
• 102000004169 proteins and genes Human genes 0.000 claims description 88
• 238000000034 method Methods 0.000 claims description 77
• 239000002773 nucleotide Substances 0.000 claims description 69
• 150000007523 nucleic acids Chemical class 0.000 claims description 68
• 125000003729 nucleotide group Chemical group 0.000 claims description 64
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 61
• 102000039446 nucleic acids Human genes 0.000 claims description 60
• 108020004707 nucleic acids Proteins 0.000 claims description 60
• 238000011282 treatment Methods 0.000 claims description 48
• 102000037865 fusion proteins Human genes 0.000 claims description 47
• 108020001507 fusion proteins Proteins 0.000 claims description 47
• 238000005534 hematocrit Methods 0.000 claims description 45
• 230000001965 increasing effect Effects 0.000 claims description 39
• 239000013598 vector Substances 0.000 claims description 38
• 206010028980 Neoplasm Diseases 0.000 claims description 37
• 241000124008 Mammalia Species 0.000 claims description 35
• 238000004519 manufacturing process Methods 0.000 claims description 34
• 208000035475 disorder Diseases 0.000 claims description 33
• 208000007502 anemia Diseases 0.000 claims description 32
• 201000010099 disease Diseases 0.000 claims description 28
• 230000014509 gene expression Effects 0.000 claims description 27
• 239000008194 pharmaceutical composition Substances 0.000 claims description 27
• 210000003169 central nervous system Anatomy 0.000 claims description 22
• 230000002669 organ and tissue protective effect Effects 0.000 claims description 22
• 108060003951 Immunoglobulin Proteins 0.000 claims description 19
• 102000018358 immunoglobulin Human genes 0.000 claims description 19
• 239000003814 drug Substances 0.000 claims description 18
• 239000002299 complementary DNA Substances 0.000 claims description 17
• 208000020832 chronic kidney disease Diseases 0.000 claims description 12
• 208000022831 chronic renal failure syndrome Diseases 0.000 claims description 12
• 201000011510 cancer Diseases 0.000 claims description 10
• 206010035226 Plasma cell myeloma Diseases 0.000 claims description 9
• 238000002512 chemotherapy Methods 0.000 claims description 9
• 210000001672 ovary Anatomy 0.000 claims description 9
• 201000006417 multiple sclerosis Diseases 0.000 claims description 8
• 208000024172 Cardiovascular disease Diseases 0.000 claims description 7
• 239000000546 pharmaceutical excipient Substances 0.000 claims description 7
• 208000024827 Alzheimer disease Diseases 0.000 claims description 6
• 206010020772 Hypertension Diseases 0.000 claims description 6
• 206010025323 Lymphomas Diseases 0.000 claims description 6
• 208000034578 Multiple myelomas Diseases 0.000 claims description 6
• 208000018737 Parkinson disease Diseases 0.000 claims description 6
• 238000000502 dialysis Methods 0.000 claims description 6
• 208000032839 leukemia Diseases 0.000 claims description 6
• 210000001428 peripheral nervous system Anatomy 0.000 claims description 6
• 239000003381 stabilizer Substances 0.000 claims description 6
• 102000011022 Chorionic Gonadotropin Human genes 0.000 claims description 5
• 108010062540 Chorionic Gonadotropin Proteins 0.000 claims description 5
• 206010060860 Neurological symptom Diseases 0.000 claims description 5
• 206010037180 Psychiatric symptoms Diseases 0.000 claims description 5
• 206010063837 Reperfusion injury Diseases 0.000 claims description 5
• 210000000481 breast Anatomy 0.000 claims description 5
• 239000003937 drug carrier Substances 0.000 claims description 5
• 229940084986 human chorionic gonadotropin Drugs 0.000 claims description 5
• 208000012947 ischemia reperfusion injury Diseases 0.000 claims description 5
• 208000010125 myocardial infarction Diseases 0.000 claims description 5
• 230000000926 neurological effect Effects 0.000 claims description 5
• 210000001236 prokaryotic cell Anatomy 0.000 claims description 5
• 230000009385 viral infection Effects 0.000 claims description 5
• HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 claims description 5
• 229960002555 zidovudine Drugs 0.000 claims description 5
• 208000006136 Leigh Disease Diseases 0.000 claims description 4
• 208000017507 Leigh syndrome Diseases 0.000 claims description 4
• 208000036142 Viral infection Diseases 0.000 claims description 4
• 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 4
• 210000002307 prostate Anatomy 0.000 claims description 4
• 208000030760 Anaemia of chronic disease Diseases 0.000 claims description 3
• 206010024291 Leukaemias acute myeloid Diseases 0.000 claims description 3
• 208000022400 anemia due to chronic disease Diseases 0.000 claims description 3
• 210000003527 eukaryotic cell Anatomy 0.000 claims description 3
• 238000001959 radiotherapy Methods 0.000 claims description 3
• 208000015347 renal cell adenocarcinoma Diseases 0.000 claims description 3
• 238000012258 culturing Methods 0.000 claims description 2
• 229940088597 hormone Drugs 0.000 claims description 2
• 239000005556 hormone Substances 0.000 claims description 2
• 201000008274 breast adenocarcinoma Diseases 0.000 claims 1
• 208000013371 ovarian adenocarcinoma Diseases 0.000 claims 1
• 201000005825 prostate adenocarcinoma Diseases 0.000 claims 1
• 235000001014 amino acid Nutrition 0.000 description 417
• 229940024606 amino acid Drugs 0.000 description 406
• 235000018102 proteins Nutrition 0.000 description 84
• 230000013595 glycosylation Effects 0.000 description 64
• 238000006206 glycosylation reaction Methods 0.000 description 64
• 230000035772 mutation Effects 0.000 description 64
• 239000012634 fragment Substances 0.000 description 60
• 230000004071 biological effect Effects 0.000 description 43
• 230000000295 complement effect Effects 0.000 description 34
• 108091032973 (ribonucleotides)n+m Proteins 0.000 description 32
• 102220093399 rs876661214 Human genes 0.000 description 30
• 230000000694 effects Effects 0.000 description 29
• 230000002103 transcriptional effect Effects 0.000 description 29
• 102220534664 Protein quaking_C34S_mutation Human genes 0.000 description 28
• 230000027455 binding Effects 0.000 description 28
• 238000006467 substitution reaction Methods 0.000 description 27
• 108020004414 DNA Proteins 0.000 description 26
• 150000002482 oligosaccharides Polymers 0.000 description 26
• 239000013615 primer Substances 0.000 description 25
• XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical group SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 24
• 239000000523 sample Substances 0.000 description 24
• 108010076504 Protein Sorting Signals Proteins 0.000 description 23
• 238000000338 in vitro Methods 0.000 description 23
• 102220534805 Protein quaking_K79A_mutation Human genes 0.000 description 22
• 102220618553 Cerebellin-3_Y42A_mutation Human genes 0.000 description 21
• 102220604132 Homeobox protein SIX3_K72D_mutation Human genes 0.000 description 21
• 102220507171 Putative microRNA 17 host gene protein_K72A_mutation Human genes 0.000 description 21
• SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 21
• 238000001727 in vivo Methods 0.000 description 21
• 229920001542 oligosaccharide Polymers 0.000 description 20
• 241001465754 Metazoa Species 0.000 description 19
• 210000003743 erythrocyte Anatomy 0.000 description 18
• 108700024394 Exon Proteins 0.000 description 17
• 125000000539 amino acid group Chemical group 0.000 description 17
• 150000001720 carbohydrates Chemical class 0.000 description 17
• SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 17
• 108020004705 Codon Proteins 0.000 description 16
• 239000000427 antigen Substances 0.000 description 16
• 108091007433 antigens Proteins 0.000 description 16
• 102000036639 antigens Human genes 0.000 description 16
• 239000000203 mixture Substances 0.000 description 16
• 229940124452 immunizing agent Drugs 0.000 description 15
• 102000008394 Immunoglobulin Fragments Human genes 0.000 description 14
• 108010021625 Immunoglobulin Fragments Proteins 0.000 description 14
• 210000004369 blood Anatomy 0.000 description 14
• 239000008280 blood Substances 0.000 description 14
• 230000000324 neuroprotective effect Effects 0.000 description 14
• 230000000508 neurotrophic effect Effects 0.000 description 14
• 229920001223 polyethylene glycol Polymers 0.000 description 14
• 101000987586 Homo sapiens Eosinophil peroxidase Proteins 0.000 description 13
• 239000002202 Polyethylene glycol Substances 0.000 description 13
• 108020004459 Small interfering RNA Proteins 0.000 description 13
• 235000014633 carbohydrates Nutrition 0.000 description 13
• 102000044890 human EPO Human genes 0.000 description 13
• 108020004999 messenger RNA Proteins 0.000 description 13
• 102220491156 ADP-ribosylation factor-like protein 14_R41A_mutation Human genes 0.000 description 12
• 102220553677 APC membrane recruitment protein 1_E48A_mutation Human genes 0.000 description 12
• 102220532591 Chromaffin granule amine transporter_S98T_mutation Human genes 0.000 description 12
• 102220497007 Erythropoietin_D70N_mutation Human genes 0.000 description 12
• 102220604084 Homeobox protein SIX3_E40A_mutation Human genes 0.000 description 12
• 102220511953 Replication protein A 70 kDa DNA-binding subunit_R41E_mutation Human genes 0.000 description 12
• 102220506631 Small ubiquitin-related modifier 3_I33A_mutation Human genes 0.000 description 12
• 102220536966 Transcription factor JunD_K47A_mutation Human genes 0.000 description 12
• 102220535819 Transcription factor JunD_K47E_mutation Human genes 0.000 description 12
• 238000007792 addition Methods 0.000 description 12
• 238000010367 cloning Methods 0.000 description 12
• 210000003734 kidney Anatomy 0.000 description 12
• 239000000047 product Substances 0.000 description 12
• 230000004224 protection Effects 0.000 description 12
• 102220198289 rs1057519954 Human genes 0.000 description 12
• 102200068503 rs121964997 Human genes 0.000 description 12
• 102200062902 rs139401671 Human genes 0.000 description 12
• 102220045411 rs587782084 Human genes 0.000 description 12
• 102220532774 von Willebrand factor A domain-containing protein 5A_L39Y_mutation Human genes 0.000 description 12
• 102000040650 (ribonucleotides)n+m Human genes 0.000 description 11
• 238000009396 hybridization Methods 0.000 description 11
• 208000014674 injury Diseases 0.000 description 11
• 230000004048 modification Effects 0.000 description 11
• 238000012986 modification Methods 0.000 description 11
• 230000008707 rearrangement Effects 0.000 description 11
• 150000003839 salts Chemical class 0.000 description 11
• -1 stem-cell factor Proteins 0.000 description 11
• 210000001519 tissue Anatomy 0.000 description 11
• 102000003886 Glycoproteins Human genes 0.000 description 10
• 108090000288 Glycoproteins Proteins 0.000 description 10
• 230000004988 N-glycosylation Effects 0.000 description 10
• 102220514467 SERTA domain-containing protein 1_L97A_mutation Human genes 0.000 description 10
• 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 description 10
• 229940127089 cytotoxic agent Drugs 0.000 description 10
• 238000012217 deletion Methods 0.000 description 10
• 230000037430 deletion Effects 0.000 description 10
• 239000013604 expression vector Substances 0.000 description 10
• 239000007924 injection Substances 0.000 description 10
• 238000002347 injection Methods 0.000 description 10
• 208000028867 ischemia Diseases 0.000 description 10
• 230000000717 retained effect Effects 0.000 description 10
• 238000012360 testing method Methods 0.000 description 10
• 239000003981 vehicle Substances 0.000 description 10
• 102220545768 116 kDa U5 small nuclear ribonucleoprotein component_C60S_mutation Human genes 0.000 description 9
• 208000030507 AIDS Diseases 0.000 description 9
• 102220486134 Alpha-galactosidase A_C56Y_mutation Human genes 0.000 description 9
• 102220470969 Carcinoembryonic antigen-related cell adhesion molecule 5_V73A_mutation Human genes 0.000 description 9
• 101150002621 EPO gene Proteins 0.000 description 9
• 102220604126 Homeobox protein SIX3_D70A_mutation Human genes 0.000 description 9
• 102220546673 Insulin-like growth factor-binding protein complex acid labile subunit_Y76A_mutation Human genes 0.000 description 9
• 102220498087 Lipoma-preferred partner_Y76S_mutation Human genes 0.000 description 9
• 102220507216 Putative microRNA 17 host gene protein_C56S_mutation Human genes 0.000 description 9
• 102220469353 Putative uncharacterized protein URB1-AS1_N74A_mutation Human genes 0.000 description 9
• 102220536879 Transcription factor JunD_F75W_mutation Human genes 0.000 description 9
• 238000006243 chemical reaction Methods 0.000 description 9
• 210000004408 hybridoma Anatomy 0.000 description 9
• 102000005962 receptors Human genes 0.000 description 9
• 108020003175 receptors Proteins 0.000 description 9
• 102200121812 rs1085307172 Human genes 0.000 description 9
• 102220004986 rs121913549 Human genes 0.000 description 9
• 102200058972 rs28940576 Human genes 0.000 description 9
• 102220041129 rs529720410 Human genes 0.000 description 9
• 125000005629 sialic acid group Chemical group 0.000 description 9
• 230000008733 trauma Effects 0.000 description 9
• YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 8
• KISWVXRQTGLFGD-UHFFFAOYSA-N 2-[[2-[[6-amino-2-[[2-[[2-[[5-amino-2-[[2-[[1-[2-[[6-amino-2-[(2,5-diamino-5-oxopentanoyl)amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-(diaminomethylideneamino)p Chemical compound C1CCN(C(=O)C(CCCN=C(N)N)NC(=O)C(CCCCN)NC(=O)C(N)CCC(N)=O)C1C(=O)NC(CO)C(=O)NC(CCC(N)=O)C(=O)NC(CCCN=C(N)N)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(C(=O)NC(CC(C)C)C(O)=O)CC1=CC=C(O)C=C1 KISWVXRQTGLFGD-UHFFFAOYSA-N 0.000 description 8
• 102000053602 DNA Human genes 0.000 description 8
• 108091028043 Nucleic acid sequence Proteins 0.000 description 8
• 208000006265 Renal cell carcinoma Diseases 0.000 description 8
• AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 8
• 239000004473 Threonine Substances 0.000 description 8
• 150000001875 compounds Chemical class 0.000 description 8
• 210000004962 mammalian cell Anatomy 0.000 description 8
• 210000005036 nerve Anatomy 0.000 description 8
• 241000699666 Mus <mouse, genus> Species 0.000 description 7
• 210000004556 brain Anatomy 0.000 description 7
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 7
• 230000003293 cardioprotective effect Effects 0.000 description 7
• 235000018417 cysteine Nutrition 0.000 description 7
• XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 7
• 230000006378 damage Effects 0.000 description 7
• 238000005516 engineering process Methods 0.000 description 7
• 229920000642 polymer Polymers 0.000 description 7
• 210000002966 serum Anatomy 0.000 description 7
• 239000000725 suspension Substances 0.000 description 7
• 239000004475 Arginine Substances 0.000 description 6
• 208000023275 Autoimmune disease Diseases 0.000 description 6
• 108091026890 Coding region Proteins 0.000 description 6
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
• 101000920686 Homo sapiens Erythropoietin Proteins 0.000 description 6
• 108091034117 Oligonucleotide Proteins 0.000 description 6
• DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
• 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 6
• 239000002671 adjuvant Substances 0.000 description 6
• 230000000692 anti-sense effect Effects 0.000 description 6
• ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 6
• 230000008901 benefit Effects 0.000 description 6
• 230000015572 biosynthetic process Effects 0.000 description 6
• 210000004899 c-terminal region Anatomy 0.000 description 6
• 239000002254 cytotoxic agent Substances 0.000 description 6
• 231100000599 cytotoxic agent Toxicity 0.000 description 6
• 229940079593 drug Drugs 0.000 description 6
• 230000009368 gene silencing by RNA Effects 0.000 description 6
• 239000003550 marker Substances 0.000 description 6
• 208000015122 neurodegenerative disease Diseases 0.000 description 6
• 239000013612 plasmid Substances 0.000 description 6
• 230000002829 reductive effect Effects 0.000 description 6
• 210000004116 schwann cell Anatomy 0.000 description 6
• 230000000638 stimulation Effects 0.000 description 6
• 238000001356 surgical procedure Methods 0.000 description 6
• 238000003786 synthesis reaction Methods 0.000 description 6
• 230000001225 therapeutic effect Effects 0.000 description 6
• 239000003053 toxin Substances 0.000 description 6
• 231100000765 toxin Toxicity 0.000 description 6
• 108700012359 toxins Proteins 0.000 description 6
• 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 5
• 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 5
• 208000017604 Hodgkin disease Diseases 0.000 description 5
• 208000021519 Hodgkin lymphoma Diseases 0.000 description 5
• 208000010747 Hodgkins lymphoma Diseases 0.000 description 5
• 206010021143 Hypoxia Diseases 0.000 description 5
• 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 5
• 102000047918 Myelin Basic Human genes 0.000 description 5
• 101710107068 Myelin basic protein Proteins 0.000 description 5
• 206010029260 Neuroblastoma Diseases 0.000 description 5
• 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 5
• MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 5
• 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 description 5
• 239000002253 acid Substances 0.000 description 5
• 230000002378 acidificating effect Effects 0.000 description 5
• 238000003556 assay Methods 0.000 description 5
• 238000004113 cell culture Methods 0.000 description 5
• 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 5
• 230000002950 deficient Effects 0.000 description 5
• 201000003444 follicular lymphoma Diseases 0.000 description 5
• 208000005017 glioblastoma Diseases 0.000 description 5
• 230000012010 growth Effects 0.000 description 5
• 239000001963 growth medium Substances 0.000 description 5
• 229940072221 immunoglobulins Drugs 0.000 description 5
• 201000001441 melanoma Diseases 0.000 description 5
• 201000000050 myeloid neoplasm Diseases 0.000 description 5
• 230000004770 neurodegeneration Effects 0.000 description 5
• 239000000825 pharmaceutical preparation Substances 0.000 description 5
• 229940127557 pharmaceutical product Drugs 0.000 description 5
• 238000000746 purification Methods 0.000 description 5
• 230000009467 reduction Effects 0.000 description 5
• 230000001105 regulatory effect Effects 0.000 description 5
• 210000003497 sciatic nerve Anatomy 0.000 description 5
• 210000000278 spinal cord Anatomy 0.000 description 5
• 230000004936 stimulating effect Effects 0.000 description 5
• 230000004083 survival effect Effects 0.000 description 5
• 208000024891 symptom Diseases 0.000 description 5
• MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 4
• VPFUWHKTPYPNGT-UHFFFAOYSA-N 3-(3,4-dihydroxyphenyl)-1-(5-hydroxy-2,2-dimethylchromen-6-yl)propan-1-one Chemical compound OC1=C2C=CC(C)(C)OC2=CC=C1C(=O)CCC1=CC=C(O)C(O)=C1 VPFUWHKTPYPNGT-UHFFFAOYSA-N 0.000 description 4
• 208000007848 Alcoholism Diseases 0.000 description 4
• 206010003571 Astrocytoma Diseases 0.000 description 4
• 201000009030 Carcinoma Diseases 0.000 description 4
• 206010007558 Cardiac failure chronic Diseases 0.000 description 4
• 206010009944 Colon cancer Diseases 0.000 description 4
• 208000035473 Communicable disease Diseases 0.000 description 4
• 241000699802 Cricetulus griseus Species 0.000 description 4
• 208000032131 Diabetic Neuropathies Diseases 0.000 description 4
• 206010012689 Diabetic retinopathy Diseases 0.000 description 4
• 241000196324 Embryophyta Species 0.000 description 4
• 108010074604 Epoetin Alfa Proteins 0.000 description 4
• WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 4
• 241000238631 Hexapoda Species 0.000 description 4
• 108010091358 Hypoxanthine Phosphoribosyltransferase Proteins 0.000 description 4
• 206010061218 Inflammation Diseases 0.000 description 4
• ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 4
• 102220507166 MICOS complex subunit MIC25_A95S_mutation Human genes 0.000 description 4
• SQVRNKJHWKZAKO-PFQGKNLYSA-N N-acetyl-beta-neuraminic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-PFQGKNLYSA-N 0.000 description 4
• 108091093037 Peptide nucleic acid Proteins 0.000 description 4
• 102100024952 Protein CBFA2T1 Human genes 0.000 description 4
• 240000004808 Saccharomyces cerevisiae Species 0.000 description 4
• IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 4
• 206010000891 acute myocardial infarction Diseases 0.000 description 4
• 208000009956 adenocarcinoma Diseases 0.000 description 4
• 239000000556 agonist Substances 0.000 description 4
• 201000007930 alcohol dependence Diseases 0.000 description 4
• 125000003277 amino group Chemical group 0.000 description 4
• 239000002246 antineoplastic agent Substances 0.000 description 4
• 238000013459 approach Methods 0.000 description 4
• 229960002685 biotin Drugs 0.000 description 4
• 235000020958 biotin Nutrition 0.000 description 4
• 239000011616 biotin Substances 0.000 description 4
• 125000004432 carbon atom Chemical group C* 0.000 description 4
• 239000012228 culture supernatant Substances 0.000 description 4
• 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 4
• 230000007423 decrease Effects 0.000 description 4
• 230000002255 enzymatic effect Effects 0.000 description 4
• 206010015037 epilepsy Diseases 0.000 description 4
• 235000013922 glutamic acid Nutrition 0.000 description 4
• 239000004220 glutamic acid Substances 0.000 description 4
• ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 4
• 150000002337 glycosamines Chemical class 0.000 description 4
• 230000004054 inflammatory process Effects 0.000 description 4
• 239000003112 inhibitor Substances 0.000 description 4
• 230000000977 initiatory effect Effects 0.000 description 4
• 208000022013 kidney Wilms tumor Diseases 0.000 description 4
• 208000002780 macular degeneration Diseases 0.000 description 4
• 239000002609 medium Substances 0.000 description 4
• 210000003205 muscle Anatomy 0.000 description 4
• 230000006320 pegylation Effects 0.000 description 4
• 230000000704 physical effect Effects 0.000 description 4
• 239000002243 precursor Substances 0.000 description 4
• 230000017854 proteolysis Effects 0.000 description 4
• 230000005855 radiation Effects 0.000 description 4
• 230000002285 radioactive effect Effects 0.000 description 4
• 201000003233 renal Wilms' tumor Diseases 0.000 description 4
• 230000002207 retinal effect Effects 0.000 description 4
• 208000032253 retinal ischemia Diseases 0.000 description 4
• 201000000980 schizophrenia Diseases 0.000 description 4
• 230000028327 secretion Effects 0.000 description 4
• 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 4
• 238000002741 site-directed mutagenesis Methods 0.000 description 4
• 239000002904 solvent Substances 0.000 description 4
• 230000004960 subcellular localization Effects 0.000 description 4
• 229940124597 therapeutic agent Drugs 0.000 description 4
• 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 4
• 231100000331 toxic Toxicity 0.000 description 4
• 230000002588 toxic effect Effects 0.000 description 4
• 238000011144 upstream manufacturing Methods 0.000 description 4
• 230000002485 urinary effect Effects 0.000 description 4
• 210000005253 yeast cell Anatomy 0.000 description 4
• VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 3
• QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
• 208000000044 Amnesia Diseases 0.000 description 3
• 206010002383 Angina Pectoris Diseases 0.000 description 3
• 108020000948 Antisense Oligonucleotides Proteins 0.000 description 3
• 208000019901 Anxiety disease Diseases 0.000 description 3
• 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 3
• 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 description 3
• 206010003805 Autism Diseases 0.000 description 3
• 208000020706 Autistic disease Diseases 0.000 description 3
• 208000019838 Blood disease Diseases 0.000 description 3
• 206010006187 Breast cancer Diseases 0.000 description 3
• 125000001433 C-terminal amino-acid group Chemical group 0.000 description 3
• 206010007572 Cardiac hypertrophy Diseases 0.000 description 3
• 208000006029 Cardiomegaly Diseases 0.000 description 3
• 241000282693 Cercopithecidae Species 0.000 description 3
• 201000006306 Cor pulmonale Diseases 0.000 description 3
• 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 description 3
• 206010012289 Dementia Diseases 0.000 description 3
• IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
• 208000018522 Gastrointestinal disease Diseases 0.000 description 3
• 208000010412 Glaucoma Diseases 0.000 description 3
• DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 3
• 208000010496 Heart Arrest Diseases 0.000 description 3
• 208000001953 Hypotension Diseases 0.000 description 3
• 102100029098 Hypoxanthine-guanine phosphoribosyltransferase Human genes 0.000 description 3
• 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 3
• 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 3
• FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 3
• OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 3
• 208000026139 Memory disease Diseases 0.000 description 3
• 208000019022 Mood disease Diseases 0.000 description 3
• 241001529936 Murinae Species 0.000 description 3
• 241000699670 Mus sp. Species 0.000 description 3
• MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
• 241000700159 Rattus Species 0.000 description 3
• 108020004511 Recombinant DNA Proteins 0.000 description 3
• 241000283984 Rodentia Species 0.000 description 3
• 108091027967 Small hairpin RNA Proteins 0.000 description 3
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
• 208000006011 Stroke Diseases 0.000 description 3
• 108010022394 Threonine synthase Proteins 0.000 description 3
• JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 3
• 230000036982 action potential Effects 0.000 description 3
• 239000004480 active ingredient Substances 0.000 description 3
• 239000000074 antisense oligonucleotide Substances 0.000 description 3
• 238000012230 antisense oligonucleotides Methods 0.000 description 3
• 230000006907 apoptotic process Effects 0.000 description 3
• QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
• 208000015802 attention deficit-hyperactivity disease Diseases 0.000 description 3
• 210000001185 bone marrow Anatomy 0.000 description 3
• 239000000872 buffer Substances 0.000 description 3
• 238000010804 cDNA synthesis Methods 0.000 description 3
• 239000000969 carrier Substances 0.000 description 3
• 230000015556 catabolic process Effects 0.000 description 3
• 230000005779 cell damage Effects 0.000 description 3
• 230000030833 cell death Effects 0.000 description 3
• 206010008129 cerebral palsy Diseases 0.000 description 3
• 238000012512 characterization method Methods 0.000 description 3
• 239000003795 chemical substances by application Substances 0.000 description 3
• 210000004978 chinese hamster ovary cell Anatomy 0.000 description 3
• 230000003920 cognitive function Effects 0.000 description 3
• 238000006731 degradation reaction Methods 0.000 description 3
• 238000001514 detection method Methods 0.000 description 3
• 102000004419 dihydrofolate reductase Human genes 0.000 description 3
• 239000000539 dimer Substances 0.000 description 3
• 239000002552 dosage form Substances 0.000 description 3
• 230000002124 endocrine Effects 0.000 description 3
• 230000000925 erythroid effect Effects 0.000 description 3
• 238000002474 experimental method Methods 0.000 description 3
• 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 3
• 208000014951 hematologic disease Diseases 0.000 description 3
• 208000018706 hematopoietic system disease Diseases 0.000 description 3
• 206010073071 hepatocellular carcinoma Diseases 0.000 description 3
• 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
• 208000013403 hyperactivity Diseases 0.000 description 3
• 230000036543 hypotension Effects 0.000 description 3
• 230000007954 hypoxia Effects 0.000 description 3
• 229940127121 immunoconjugate Drugs 0.000 description 3
• 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 description 3
• 230000006698 induction Effects 0.000 description 3
• 238000001990 intravenous administration Methods 0.000 description 3
• 208000017169 kidney disease Diseases 0.000 description 3
• 230000000670 limiting effect Effects 0.000 description 3
• 210000004698 lymphocyte Anatomy 0.000 description 3
• 239000000463 material Substances 0.000 description 3
• 239000011159 matrix material Substances 0.000 description 3
• 230000006984 memory degeneration Effects 0.000 description 3
• 208000023060 memory loss Diseases 0.000 description 3
• 230000006371 metabolic abnormality Effects 0.000 description 3
• 229930182817 methionine Natural products 0.000 description 3
• 210000002569 neuron Anatomy 0.000 description 3
• 229910052760 oxygen Inorganic materials 0.000 description 3
• 239000001301 oxygen Substances 0.000 description 3
• 238000007911 parenteral administration Methods 0.000 description 3
• 230000008569 process Effects 0.000 description 3
• 230000035755 proliferation Effects 0.000 description 3
• 238000011321 prophylaxis Methods 0.000 description 3
• 238000003127 radioimmunoassay Methods 0.000 description 3
• 230000010076 replication Effects 0.000 description 3
• 208000017443 reproductive system disease Diseases 0.000 description 3
• 208000023504 respiratory system disease Diseases 0.000 description 3
• 238000003757 reverse transcription PCR Methods 0.000 description 3
• 238000012552 review Methods 0.000 description 3
• 239000008159 sesame oil Substances 0.000 description 3
• 235000011803 sesame oil Nutrition 0.000 description 3
• 238000010532 solid phase synthesis reaction Methods 0.000 description 3
• 238000007619 statistical method Methods 0.000 description 3
• 238000007920 subcutaneous administration Methods 0.000 description 3
• 239000000126 substance Substances 0.000 description 3
• 238000013518 transcription Methods 0.000 description 3
• 230000035897 transcription Effects 0.000 description 3
• 230000014616 translation Effects 0.000 description 3
• 241000701447 unidentified baculovirus Species 0.000 description 3
• 208000014001 urinary system disease Diseases 0.000 description 3
• 230000003612 virological effect Effects 0.000 description 3
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
• 229920003169 water-soluble polymer Polymers 0.000 description 3
• VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
• FBUTXZSKZCQABC-UHFFFAOYSA-N 2-amino-1-methyl-7h-purine-6-thione Chemical compound S=C1N(C)C(N)=NC2=C1NC=N2 FBUTXZSKZCQABC-UHFFFAOYSA-N 0.000 description 2
• 108010066676 Abrin Proteins 0.000 description 2
• 206010073128 Anaplastic oligodendroglioma Diseases 0.000 description 2
• 206010003445 Ascites Diseases 0.000 description 2
• 101000669426 Aspergillus restrictus Ribonuclease mitogillin Proteins 0.000 description 2
• 108090001008 Avidin Proteins 0.000 description 2
• 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 2
• 241000894006 Bacteria Species 0.000 description 2
• 206010004146 Basal cell carcinoma Diseases 0.000 description 2
• DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 2
• 206010005003 Bladder cancer Diseases 0.000 description 2
• 241000283690 Bos taurus Species 0.000 description 2
• 208000026310 Breast neoplasm Diseases 0.000 description 2
• 238000011740 C57BL/6 mouse Methods 0.000 description 2
• OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
• 241000282832 Camelidae Species 0.000 description 2
• 101710158575 Cap-specific mRNA (nucleoside-2'-O-)-methyltransferase Proteins 0.000 description 2
• 206010008342 Cervix carcinoma Diseases 0.000 description 2
• 208000001333 Colorectal Neoplasms Diseases 0.000 description 2
• 108020004635 Complementary DNA Proteins 0.000 description 2
• 241000699800 Cricetinae Species 0.000 description 2
• 108700032819 Croton tiglium crotin II Proteins 0.000 description 2
• 229920002307 Dextran Polymers 0.000 description 2
• 108010053187 Diphtheria Toxin Proteins 0.000 description 2
• 102000016607 Diphtheria Toxin Human genes 0.000 description 2
• 206010014733 Endometrial cancer Diseases 0.000 description 2
• 206010014759 Endometrial neoplasm Diseases 0.000 description 2
• 102100031780 Endonuclease Human genes 0.000 description 2
• 102000005593 Endopeptidases Human genes 0.000 description 2
• 108010059378 Endopeptidases Proteins 0.000 description 2
• 108010075944 Erythropoietin Receptors Proteins 0.000 description 2
• 102100036509 Erythropoietin receptor Human genes 0.000 description 2
• 241000588724 Escherichia coli Species 0.000 description 2
• 208000000461 Esophageal Neoplasms Diseases 0.000 description 2
• 102000018389 Exopeptidases Human genes 0.000 description 2
• 108010091443 Exopeptidases Proteins 0.000 description 2
• 101710082714 Exotoxin A Proteins 0.000 description 2
• 108091092584 GDNA Proteins 0.000 description 2
• 206010017993 Gastrointestinal neoplasms Diseases 0.000 description 2
• 108010010803 Gelatin Proteins 0.000 description 2
• 108700004714 Gelonium multiflorum GEL Proteins 0.000 description 2
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
• NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 2
• 241000520223 Helice Species 0.000 description 2
• 208000005176 Hepatitis C Diseases 0.000 description 2
• 208000007514 Herpes zoster Diseases 0.000 description 2
• VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
• 208000032382 Ischaemic stroke Diseases 0.000 description 2
• 208000007766 Kaposi sarcoma Diseases 0.000 description 2
• 208000008839 Kidney Neoplasms Diseases 0.000 description 2
• WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
• KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
• 239000004472 Lysine Substances 0.000 description 2
• 208000000172 Medulloblastoma Diseases 0.000 description 2
• 244000302512 Momordica charantia Species 0.000 description 2
• 235000009811 Momordica charantia Nutrition 0.000 description 2
• 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 2
• 206010028851 Necrosis Diseases 0.000 description 2
• 208000028389 Nerve injury Diseases 0.000 description 2
• MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
• 101710163270 Nuclease Proteins 0.000 description 2
• 206010030155 Oesophageal carcinoma Diseases 0.000 description 2
• 201000010133 Oligodendroglioma Diseases 0.000 description 2
• 241000283973 Oryctolagus cuniculus Species 0.000 description 2
• 206010033128 Ovarian cancer Diseases 0.000 description 2
• 206010061535 Ovarian neoplasm Diseases 0.000 description 2
• 206010061902 Pancreatic neoplasm Diseases 0.000 description 2
• 101100413173 Phytolacca americana PAP2 gene Proteins 0.000 description 2
• NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
• NBBJYMSMWIIQGU-UHFFFAOYSA-N Propionic aldehyde Chemical compound CCC=O NBBJYMSMWIIQGU-UHFFFAOYSA-N 0.000 description 2
• 206010060862 Prostate cancer Diseases 0.000 description 2
• 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
• 108010029485 Protein Isoforms Proteins 0.000 description 2
• 102000001708 Protein Isoforms Human genes 0.000 description 2
• 101710130181 Protochlorophyllide reductase A, chloroplastic Proteins 0.000 description 2
• 241000589517 Pseudomonas aeruginosa Species 0.000 description 2
• 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 2
• 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
• 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
• 206010038389 Renal cancer Diseases 0.000 description 2
• 108010039491 Ricin Proteins 0.000 description 2
• 206010061934 Salivary gland cancer Diseases 0.000 description 2
• 206010039491 Sarcoma Diseases 0.000 description 2
• 206010041067 Small cell lung cancer Diseases 0.000 description 2
• 108091081024 Start codon Proteins 0.000 description 2
• QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
• 208000024313 Testicular Neoplasms Diseases 0.000 description 2
• 206010057644 Testis cancer Diseases 0.000 description 2
• 208000024770 Thyroid neoplasm Diseases 0.000 description 2
• ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
• DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical class O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 2
• 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 2
• 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 2
• 240000001866 Vernicia fordii Species 0.000 description 2
• 241000700605 Viruses Species 0.000 description 2
• 206010047741 Vulval cancer Diseases 0.000 description 2
• 208000027418 Wounds and injury Diseases 0.000 description 2
• 230000009471 action Effects 0.000 description 2
• 238000005917 acylation reaction Methods 0.000 description 2
• OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
• 238000001042 affinity chromatography Methods 0.000 description 2
• 150000001299 aldehydes Chemical class 0.000 description 2
• 238000005804 alkylation reaction Methods 0.000 description 2
• 108010001818 alpha-sarcin Proteins 0.000 description 2
• 206010002224 anaplastic astrocytoma Diseases 0.000 description 2
• 208000013938 anaplastic oligoastrocytoma Diseases 0.000 description 2
• 239000005557 antagonist Substances 0.000 description 2
• 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 2
• 230000001580 bacterial effect Effects 0.000 description 2
• IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 2
• 238000004166 bioassay Methods 0.000 description 2
• 201000000053 blastoma Diseases 0.000 description 2
• 210000001772 blood platelet Anatomy 0.000 description 2
• 239000011575 calcium Substances 0.000 description 2
• 229910052791 calcium Inorganic materials 0.000 description 2
• 210000004413 cardiac myocyte Anatomy 0.000 description 2
• 239000001913 cellulose Substances 0.000 description 2
• 229920002678 cellulose Polymers 0.000 description 2
• 201000010881 cervical cancer Diseases 0.000 description 2
• 238000012411 cloning technique Methods 0.000 description 2
• 239000013599 cloning vector Substances 0.000 description 2
• 208000029742 colonic neoplasm Diseases 0.000 description 2
• 239000000356 contaminant Substances 0.000 description 2
• 239000007822 coupling agent Substances 0.000 description 2
• 238000004132 cross linking Methods 0.000 description 2
• 230000007123 defense Effects 0.000 description 2
• 230000007812 deficiency Effects 0.000 description 2
• 229930191339 dianthin Natural products 0.000 description 2
• 235000014113 dietary fatty acids Nutrition 0.000 description 2
• 239000003085 diluting agent Substances 0.000 description 2
• 206010013023 diphtheria Diseases 0.000 description 2
• 238000012377 drug delivery Methods 0.000 description 2
• 238000004520 electroporation Methods 0.000 description 2
• 201000008184 embryoma Diseases 0.000 description 2
• 201000003914 endometrial carcinoma Diseases 0.000 description 2
• 108010028531 enomycin Proteins 0.000 description 2
• 201000004101 esophageal cancer Diseases 0.000 description 2
• 150000002148 esters Chemical class 0.000 description 2
• 239000000194 fatty acid Substances 0.000 description 2
• 229930195729 fatty acid Natural products 0.000 description 2
• 125000000524 functional group Chemical group 0.000 description 2
• 230000002538 fungal effect Effects 0.000 description 2
• 230000004927 fusion Effects 0.000 description 2
• 239000008273 gelatin Substances 0.000 description 2
• 229920000159 gelatin Polymers 0.000 description 2
• 235000019322 gelatine Nutrition 0.000 description 2
• 235000011852 gelatine desserts Nutrition 0.000 description 2
• 230000003394 haemopoietic effect Effects 0.000 description 2
• 201000010536 head and neck cancer Diseases 0.000 description 2
• 208000014829 head and neck neoplasm Diseases 0.000 description 2
• 230000002440 hepatic effect Effects 0.000 description 2
• 208000002672 hepatitis B Diseases 0.000 description 2
• FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
• 230000001146 hypoxic effect Effects 0.000 description 2
• 230000002163 immunogen Effects 0.000 description 2
• 230000016784 immunoglobulin production Effects 0.000 description 2
• 238000001114 immunoprecipitation Methods 0.000 description 2
• 230000001976 improved effect Effects 0.000 description 2
• 230000001939 inductive effect Effects 0.000 description 2
• 208000037906 ischaemic injury Diseases 0.000 description 2
• 238000002955 isolation Methods 0.000 description 2
• 201000010982 kidney cancer Diseases 0.000 description 2
• 239000003446 ligand Substances 0.000 description 2
• 239000002502 liposome Substances 0.000 description 2
• 201000007270 liver cancer Diseases 0.000 description 2
• 208000014018 liver neoplasm Diseases 0.000 description 2
• HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
• 230000036210 malignancy Effects 0.000 description 2
• 208000030883 malignant astrocytoma Diseases 0.000 description 2
• 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 2
• 230000007246 mechanism Effects 0.000 description 2
• 108010010621 modeccin Proteins 0.000 description 2
• 230000017074 necrotic cell death Effects 0.000 description 2
• 239000013642 negative control Substances 0.000 description 2
• 208000004296 neuralgia Diseases 0.000 description 2
• 208000021722 neuropathic pain Diseases 0.000 description 2
• 208000002154 non-small cell lung carcinoma Diseases 0.000 description 2
• 230000009871 nonspecific binding Effects 0.000 description 2
• 210000004248 oligodendroglia Anatomy 0.000 description 2
• 210000000056 organ Anatomy 0.000 description 2
• 201000002528 pancreatic cancer Diseases 0.000 description 2
• 208000008443 pancreatic carcinoma Diseases 0.000 description 2
• 230000001575 pathological effect Effects 0.000 description 2
• 108010076042 phenomycin Proteins 0.000 description 2
• 229910052698 phosphorus Inorganic materials 0.000 description 2
• 230000026731 phosphorylation Effects 0.000 description 2
• 238000006366 phosphorylation reaction Methods 0.000 description 2
• 210000002381 plasma Anatomy 0.000 description 2
• 238000006116 polymerization reaction Methods 0.000 description 2
• 229920000136 polysorbate Polymers 0.000 description 2
• 230000004481 post-translational protein modification Effects 0.000 description 2
• 230000032361 posttranscriptional gene silencing Effects 0.000 description 2
• 230000003389 potentiating effect Effects 0.000 description 2
• 238000001556 precipitation Methods 0.000 description 2
• 238000012545 processing Methods 0.000 description 2
• 230000002035 prolonged effect Effects 0.000 description 2
• 125000006239 protecting group Chemical group 0.000 description 2
• 230000006798 recombination Effects 0.000 description 2
• 238000005215 recombination Methods 0.000 description 2
• 230000004044 response Effects 0.000 description 2
• 210000001525 retina Anatomy 0.000 description 2
• 230000001177 retroviral effect Effects 0.000 description 2
• 229920002477 rna polymer Polymers 0.000 description 2
• 201000003804 salivary gland carcinoma Diseases 0.000 description 2
• 238000013391 scatchard analysis Methods 0.000 description 2
• 208000000587 small cell lung carcinoma Diseases 0.000 description 2
• 210000000813 small intestine Anatomy 0.000 description 2
• 239000011780 sodium chloride Substances 0.000 description 2
• 239000000243 solution Substances 0.000 description 2
• 125000006850 spacer group Chemical group 0.000 description 2
• 241000894007 species Species 0.000 description 2
• 206010041823 squamous cell carcinoma Diseases 0.000 description 2
• 208000017572 squamous cell neoplasm Diseases 0.000 description 2
• 238000010561 standard procedure Methods 0.000 description 2
• 201000003120 testicular cancer Diseases 0.000 description 2
• 210000001550 testis Anatomy 0.000 description 2
• 229940104230 thymidine Drugs 0.000 description 2
• 201000002510 thyroid cancer Diseases 0.000 description 2
• 230000001988 toxicity Effects 0.000 description 2
• 231100000419 toxicity Toxicity 0.000 description 2
• 238000013519 translation Methods 0.000 description 2
• 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 2
• 241001515965 unidentified phage Species 0.000 description 2
• 201000005112 urinary bladder cancer Diseases 0.000 description 2
• 201000005102 vulva cancer Diseases 0.000 description 2
• HDTRYLNUVZCQOY-UHFFFAOYSA-N &alpha;-D-glucopyranosyl-&alpha;-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
• 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
• TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 1
• 239000013607 AAV vector Substances 0.000 description 1
• QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
• 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
• 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
• GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
• 102220486094 Alpha-galactosidase A_W47G_mutation Human genes 0.000 description 1
• QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
• 235000002198 Annona diversifolia Nutrition 0.000 description 1
• 206010059313 Anogenital warts Diseases 0.000 description 1
• DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
• 244000063299 Bacillus subtilis Species 0.000 description 1
• 235000014469 Bacillus subtilis Nutrition 0.000 description 1
• 108091032955 Bacterial small RNA Proteins 0.000 description 1
• 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
• 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
• 102100037080 C4b-binding protein beta chain Human genes 0.000 description 1
• 101100505161 Caenorhabditis elegans mel-32 gene Proteins 0.000 description 1
• 241000282828 Camelus bactrianus Species 0.000 description 1
• 241000282836 Camelus dromedarius Species 0.000 description 1
• 102000011727 Caspases Human genes 0.000 description 1
• 108010076667 Caspases Proteins 0.000 description 1
• VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
• 208000000419 Chronic Hepatitis B Diseases 0.000 description 1
• 208000006154 Chronic hepatitis C Diseases 0.000 description 1
• KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
• 206010009900 Colitis ulcerative Diseases 0.000 description 1
• 102000008186 Collagen Human genes 0.000 description 1
• 108010035532 Collagen Proteins 0.000 description 1
• 208000000907 Condylomata Acuminata Diseases 0.000 description 1
• RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
• 208000011231 Crohn disease Diseases 0.000 description 1
• MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 description 1
• 102000036364 Cullin Ring E3 Ligases Human genes 0.000 description 1
• FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
• FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
• NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 description 1
• 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
• 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
• 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
• 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
• 208000007342 Diabetic Nephropathies Diseases 0.000 description 1
• 206010012688 Diabetic retinal oedema Diseases 0.000 description 1
• 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
• 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
• LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
• 102000004190 Enzymes Human genes 0.000 description 1
• 108090000790 Enzymes Proteins 0.000 description 1
• 241000283086 Equidae Species 0.000 description 1
• 241000283074 Equus asinus Species 0.000 description 1
• 241000283073 Equus caballus Species 0.000 description 1
• 102100029951 Estrogen receptor beta Human genes 0.000 description 1
• 102220571590 Fatty acid hydroxylase domain-containing protein 2_K79N_mutation Human genes 0.000 description 1
• 102000009109 Fc receptors Human genes 0.000 description 1
• 108010087819 Fc receptors Proteins 0.000 description 1
• 108010001515 Galectin 4 Proteins 0.000 description 1
• 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
• CHDWDBPJOZVZSE-KKUMJFAQSA-N Glu-Phe-Met Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCSC)C(O)=O CHDWDBPJOZVZSE-KKUMJFAQSA-N 0.000 description 1
• 239000004471 Glycine Substances 0.000 description 1
• 244000068988 Glycine max Species 0.000 description 1
• 235000010469 Glycine max Nutrition 0.000 description 1
• 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
• 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
• 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
• 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
• 108010051696 Growth Hormone Proteins 0.000 description 1
• 108020005004 Guide RNA Proteins 0.000 description 1
• 208000031886 HIV Infections Diseases 0.000 description 1
• 208000037357 HIV infectious disease Diseases 0.000 description 1
• 102000001554 Hemoglobins Human genes 0.000 description 1
• 108010054147 Hemoglobins Proteins 0.000 description 1
• 208000032843 Hemorrhage Diseases 0.000 description 1
• 241000282412 Homo Species 0.000 description 1
• 101000740689 Homo sapiens C4b-binding protein beta chain Proteins 0.000 description 1
• 101001002709 Homo sapiens Interleukin-4 Proteins 0.000 description 1
• 101000997832 Homo sapiens Tyrosine-protein kinase JAK2 Proteins 0.000 description 1
• 108091006905 Human Serum Albumin Proteins 0.000 description 1
• 102000008100 Human Serum Albumin Human genes 0.000 description 1
• 206010020751 Hypersensitivity Diseases 0.000 description 1
• 206010062767 Hypophysitis Diseases 0.000 description 1
• UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
• 108700005091 Immunoglobulin Genes Proteins 0.000 description 1
• 102000013463 Immunoglobulin Light Chains Human genes 0.000 description 1
• 108010065825 Immunoglobulin Light Chains Proteins 0.000 description 1
• 102000012745 Immunoglobulin Subunits Human genes 0.000 description 1
• 108010079585 Immunoglobulin Subunits Proteins 0.000 description 1
• 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
• 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
• 102000004388 Interleukin-4 Human genes 0.000 description 1
• 108090000978 Interleukin-4 Proteins 0.000 description 1
• 102100039897 Interleukin-5 Human genes 0.000 description 1
• 108010002616 Interleukin-5 Proteins 0.000 description 1
• 241000235649 Kluyveromyces Species 0.000 description 1
• ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
• DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
• KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
• FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
• 241000282838 Lama Species 0.000 description 1
• 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
• 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
• 101710181812 Methionine aminopeptidase Proteins 0.000 description 1
• GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
• 125000000729 N-terminal amino-acid group Chemical group 0.000 description 1
• 108020004711 Nucleic Acid Probes Proteins 0.000 description 1
• 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
• 240000007594 Oryza sativa Species 0.000 description 1
• 235000007164 Oryza sativa Nutrition 0.000 description 1
• 238000009004 PCR Kit Methods 0.000 description 1
• 229920001734 PEG propionaldehyde Polymers 0.000 description 1
• 241001631646 Papillomaviridae Species 0.000 description 1
• 235000019483 Peanut oil Nutrition 0.000 description 1
• 206010035664 Pneumonia Diseases 0.000 description 1
• 241000276498 Pollachius virens Species 0.000 description 1
• 239000004372 Polyvinyl alcohol Substances 0.000 description 1
• 241000288906 Primates Species 0.000 description 1
• 201000004681 Psoriasis Diseases 0.000 description 1
• 239000012980 RPMI-1640 medium Substances 0.000 description 1
• 208000001647 Renal Insufficiency Diseases 0.000 description 1
• 208000017442 Retinal disease Diseases 0.000 description 1
• 206010038923 Retinopathy Diseases 0.000 description 1
• 241000235070 Saccharomyces Species 0.000 description 1
• 208000008765 Sciatica Diseases 0.000 description 1
• 229920005654 Sephadex Polymers 0.000 description 1
• 239000012507 Sephadex™ Substances 0.000 description 1
• 229920002684 Sepharose Polymers 0.000 description 1
• 108010071390 Serum Albumin Proteins 0.000 description 1
• 102000007562 Serum Albumin Human genes 0.000 description 1
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
• 102100038803 Somatotropin Human genes 0.000 description 1
• 241000256248 Spodoptera Species 0.000 description 1
• 241000269319 Squalius cephalus Species 0.000 description 1
• 229920002472 Starch Polymers 0.000 description 1
• 108010090804 Streptavidin Proteins 0.000 description 1
• 208000032851 Subarachnoid Hemorrhage Diseases 0.000 description 1
• 229930006000 Sucrose Natural products 0.000 description 1
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
• 108010034949 Thyroglobulin Proteins 0.000 description 1
• 102000009843 Thyroglobulin Human genes 0.000 description 1
• 102220520724 Toll-like receptor 1_R80T_mutation Human genes 0.000 description 1
• 231100000644 Toxic injury Toxicity 0.000 description 1
• 206010060872 Transplant failure Diseases 0.000 description 1
• HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
• GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
• 239000007983 Tris buffer Substances 0.000 description 1
• 101710162629 Trypsin inhibitor Proteins 0.000 description 1
• 229940122618 Trypsin inhibitor Drugs 0.000 description 1
• 102100033444 Tyrosine-protein kinase JAK2 Human genes 0.000 description 1
• 201000006704 Ulcerative Colitis Diseases 0.000 description 1
• 102220574784 Uncharacterized protein MISP3_N65Q_mutation Human genes 0.000 description 1
• 208000003443 Unconsciousness Diseases 0.000 description 1
• 229910052770 Uranium Inorganic materials 0.000 description 1
• 244000000188 Vaccinium ovalifolium Species 0.000 description 1
• 206010047139 Vasoconstriction Diseases 0.000 description 1
• 206010047141 Vasodilatation Diseases 0.000 description 1
• 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
• 241001416177 Vicugna pacos Species 0.000 description 1
• 239000008351 acetate buffer Substances 0.000 description 1
• DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
• 150000007513 acids Chemical class 0.000 description 1
• 230000004913 activation Effects 0.000 description 1
• 125000002252 acyl group Chemical group 0.000 description 1
• 230000010933 acylation Effects 0.000 description 1
• 239000000654 additive Substances 0.000 description 1
• 229960005305 adenosine Drugs 0.000 description 1
• 210000004404 adrenal cortex Anatomy 0.000 description 1
• 210000001943 adrenal medulla Anatomy 0.000 description 1
• 238000001261 affinity purification Methods 0.000 description 1
• 235000004279 alanine Nutrition 0.000 description 1
• 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 1
• 150000008431 aliphatic amides Chemical class 0.000 description 1
• 125000003545 alkoxy group Chemical group 0.000 description 1
• 230000029936 alkylation Effects 0.000 description 1
• 230000007815 allergy Effects 0.000 description 1
• HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
• 230000004075 alteration Effects 0.000 description 1
• 150000001412 amines Chemical class 0.000 description 1
• 229960003896 aminopterin Drugs 0.000 description 1
• 230000003321 amplification Effects 0.000 description 1
• 238000012197 amplification kit Methods 0.000 description 1
• 238000002266 amputation Methods 0.000 description 1
• 238000000137 annealing Methods 0.000 description 1
• 208000025009 anogenital human papillomavirus infection Diseases 0.000 description 1
• 201000004201 anogenital venereal wart Diseases 0.000 description 1
• 239000003242 anti bacterial agent Substances 0.000 description 1
• 230000002424 anti-apoptotic effect Effects 0.000 description 1
• 230000003110 anti-inflammatory effect Effects 0.000 description 1
• 230000000840 anti-viral effect Effects 0.000 description 1
• 229940088710 antibiotic agent Drugs 0.000 description 1
• 210000000628 antibody-producing cell Anatomy 0.000 description 1
• 230000000890 antigenic effect Effects 0.000 description 1
• 239000003963 antioxidant agent Substances 0.000 description 1
• 230000003078 antioxidant effect Effects 0.000 description 1
• 235000006708 antioxidants Nutrition 0.000 description 1
• 239000007864 aqueous solution Substances 0.000 description 1
• 125000003435 aroyl group Chemical group 0.000 description 1
• 210000004507 artificial chromosome Anatomy 0.000 description 1
• 125000003118 aryl group Chemical group 0.000 description 1
• 125000004104 aryloxy group Chemical group 0.000 description 1
• 235000009582 asparagine Nutrition 0.000 description 1
• 229960001230 asparagine Drugs 0.000 description 1
• 208000006673 asthma Diseases 0.000 description 1
• 239000012752 auxiliary agent Substances 0.000 description 1
• 230000003376 axonal effect Effects 0.000 description 1
• WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
• DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 1
• 230000003115 biocidal effect Effects 0.000 description 1
• 239000003139 biocide Substances 0.000 description 1
• 239000013060 biological fluid Substances 0.000 description 1
• 239000012620 biological material Substances 0.000 description 1
• 229920001743 bis-succinimidyl carbonate PEG Polymers 0.000 description 1
• 210000000601 blood cell Anatomy 0.000 description 1
• 238000004820 blood count Methods 0.000 description 1
• 210000001124 body fluid Anatomy 0.000 description 1
• 239000010839 body fluid Substances 0.000 description 1
• 229940098773 bovine serum albumin Drugs 0.000 description 1
• 208000029028 brain injury Diseases 0.000 description 1
• ZTQSAGDEMFDKMZ-UHFFFAOYSA-N butyric aldehyde Natural products CCCC=O ZTQSAGDEMFDKMZ-UHFFFAOYSA-N 0.000 description 1
• 239000001768 carboxy methyl cellulose Substances 0.000 description 1
• 230000005961 cardioprotection Effects 0.000 description 1
• 208000003295 carpal tunnel syndrome Diseases 0.000 description 1
• 230000032677 cell aging Effects 0.000 description 1
• 230000004663 cell proliferation Effects 0.000 description 1
• 210000001638 cerebellum Anatomy 0.000 description 1
• 238000012412 chemical coupling Methods 0.000 description 1
• 238000004587 chromatography analysis Methods 0.000 description 1
• 239000007979 citrate buffer Substances 0.000 description 1
• 238000003776 cleavage reaction Methods 0.000 description 1
• 238000012761 co-transfection Methods 0.000 description 1
• 229920001436 collagen Polymers 0.000 description 1
• 230000006835 compression Effects 0.000 description 1
• 238000007906 compression Methods 0.000 description 1
• 238000009833 condensation Methods 0.000 description 1
• 230000005494 condensation Effects 0.000 description 1
• 230000021615 conjugation Effects 0.000 description 1
• 238000010276 construction Methods 0.000 description 1
• 238000013270 controlled release Methods 0.000 description 1
• 229920001577 copolymer Polymers 0.000 description 1
• 229910052802 copper Inorganic materials 0.000 description 1
• 239000010949 copper Substances 0.000 description 1
• 210000003618 cortical neuron Anatomy 0.000 description 1
• 230000008878 coupling Effects 0.000 description 1
• 238000010168 coupling process Methods 0.000 description 1
• 238000005859 coupling reaction Methods 0.000 description 1
• 230000001419 dependent effect Effects 0.000 description 1
• 206010012601 diabetes mellitus Diseases 0.000 description 1
• 208000033679 diabetic kidney disease Diseases 0.000 description 1
• 201000011190 diabetic macular edema Diseases 0.000 description 1
• 230000004069 differentiation Effects 0.000 description 1
• 230000029087 digestion Effects 0.000 description 1
• 238000010790 dilution Methods 0.000 description 1
• 239000012895 dilution Substances 0.000 description 1
• LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
• 235000021186 dishes Nutrition 0.000 description 1
• 229940000406 drug candidate Drugs 0.000 description 1
• 238000001962 electrophoresis Methods 0.000 description 1
• 239000000839 emulsion Substances 0.000 description 1
• 230000002357 endometrial effect Effects 0.000 description 1
• 239000003623 enhancer Substances 0.000 description 1
• 229940088598 enzyme Drugs 0.000 description 1
• 210000000267 erythroid cell Anatomy 0.000 description 1
• LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
• 229940093471 ethyl oleate Drugs 0.000 description 1
• 230000003203 everyday effect Effects 0.000 description 1
• 238000000605 extraction Methods 0.000 description 1
• 210000000256 facial nerve Anatomy 0.000 description 1
• 239000010685 fatty oil Substances 0.000 description 1
• 235000013312 flour Nutrition 0.000 description 1
• 239000012530 fluid Substances 0.000 description 1
• 210000002683 foot Anatomy 0.000 description 1
• 230000006870 function Effects 0.000 description 1
• 239000000499 gel Substances 0.000 description 1
• 238000001502 gel electrophoresis Methods 0.000 description 1
• 230000002068 genetic effect Effects 0.000 description 1
• 239000008103 glucose Substances 0.000 description 1
• 229930195712 glutamate Natural products 0.000 description 1
• YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
• SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
• 102000035122 glycosylated proteins Human genes 0.000 description 1
• 108091005608 glycosylated proteins Proteins 0.000 description 1
• 239000000122 growth hormone Substances 0.000 description 1
• 229940029575 guanosine Drugs 0.000 description 1
• 230000036541 health Effects 0.000 description 1
• 210000005003 heart tissue Anatomy 0.000 description 1
• 229910001385 heavy metal Inorganic materials 0.000 description 1
• 108010057760 hepatic sialoglycoprotein receptor Proteins 0.000 description 1
• 208000010710 hepatitis C virus infection Diseases 0.000 description 1
• 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
• 230000002443 hepatoprotective effect Effects 0.000 description 1
• 210000001320 hippocampus Anatomy 0.000 description 1
• HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
• 229920001519 homopolymer Polymers 0.000 description 1
• 102000055229 human IL4 Human genes 0.000 description 1
• 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
• 230000002209 hydrophobic effect Effects 0.000 description 1
• 125000001165 hydrophobic group Chemical group 0.000 description 1
• 125000004356 hydroxy functional group Chemical group O* 0.000 description 1
• 238000012872 hydroxylapatite chromatography Methods 0.000 description 1
• 230000003053 immunization Effects 0.000 description 1
• 208000015181 infectious disease Diseases 0.000 description 1
• 230000002458 infectious effect Effects 0.000 description 1
• 230000002757 inflammatory effect Effects 0.000 description 1
• 229910052500 inorganic mineral Inorganic materials 0.000 description 1
• 230000003993 interaction Effects 0.000 description 1
• 229940028885 interleukin-4 Drugs 0.000 description 1
• 229940100602 interleukin-5 Drugs 0.000 description 1
• 230000003834 intracellular effect Effects 0.000 description 1
• 238000007918 intramuscular administration Methods 0.000 description 1
• 238000007912 intraperitoneal administration Methods 0.000 description 1
• 239000007928 intraperitoneal injection Substances 0.000 description 1
• 230000001788 irregular Effects 0.000 description 1
• 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 1
• 201000006370 kidney failure Diseases 0.000 description 1
• 239000008101 lactose Substances 0.000 description 1
• 210000000265 leukocyte Anatomy 0.000 description 1
• 239000007788 liquid Substances 0.000 description 1
• 239000007791 liquid phase Substances 0.000 description 1
• 210000004185 liver Anatomy 0.000 description 1
• 210000005229 liver cell Anatomy 0.000 description 1
• 230000007774 longterm Effects 0.000 description 1
• 210000004072 lung Anatomy 0.000 description 1
• 210000005265 lung cell Anatomy 0.000 description 1
• 210000001165 lymph node Anatomy 0.000 description 1
• 229920001427 mPEG Polymers 0.000 description 1
• 235000019359 magnesium stearate Nutrition 0.000 description 1
• 230000035800 maturation Effects 0.000 description 1
• 230000001404 mediated effect Effects 0.000 description 1
• 230000002503 metabolic effect Effects 0.000 description 1
• 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 1
• 229960000485 methotrexate Drugs 0.000 description 1
• 238000000520 microinjection Methods 0.000 description 1
• 230000003278 mimic effect Effects 0.000 description 1
• 239000011707 mineral Substances 0.000 description 1
• 239000002480 mineral oil Substances 0.000 description 1
• 235000010446 mineral oil Nutrition 0.000 description 1
• 239000003607 modifier Substances 0.000 description 1
• 229940035032 monophosphoryl lipid a Drugs 0.000 description 1
• 230000023105 myelination Effects 0.000 description 1
• 210000000107 myocyte Anatomy 0.000 description 1
• 229920005615 natural polymer Polymers 0.000 description 1
• 230000008764 nerve damage Effects 0.000 description 1
• 230000001537 neural effect Effects 0.000 description 1
• 230000014511 neuron projection development Effects 0.000 description 1
• 201000001119 neuropathy Diseases 0.000 description 1
• 230000007823 neuropathy Effects 0.000 description 1
• 230000003472 neutralizing effect Effects 0.000 description 1
• 239000012457 nonaqueous media Substances 0.000 description 1
• 238000003199 nucleic acid amplification method Methods 0.000 description 1
• 239000002853 nucleic acid probe Substances 0.000 description 1
• 235000015097 nutrients Nutrition 0.000 description 1
• 239000003921 oil Substances 0.000 description 1
• 235000019198 oils Nutrition 0.000 description 1
• 239000002751 oligonucleotide probe Substances 0.000 description 1
• 238000011275 oncology therapy Methods 0.000 description 1
• 238000001543 one-way ANOVA Methods 0.000 description 1
• 150000007524 organic acids Chemical class 0.000 description 1
• 235000005985 organic acids Nutrition 0.000 description 1
• 150000007530 organic bases Chemical class 0.000 description 1
• 239000003960 organic solvent Substances 0.000 description 1
• 230000003204 osmotic effect Effects 0.000 description 1
• 230000002611 ovarian Effects 0.000 description 1
• 235000006408 oxalic acid Nutrition 0.000 description 1
• 210000000496 pancreas Anatomy 0.000 description 1
• 239000004031 partial agonist Substances 0.000 description 1
• 239000000312 peanut oil Substances 0.000 description 1
• 230000010412 perfusion Effects 0.000 description 1
• 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 1
• 208000033808 peripheral neuropathy Diseases 0.000 description 1
• 239000003208 petroleum Substances 0.000 description 1
• 238000002823 phage display Methods 0.000 description 1
• WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
• 239000008363 phosphate buffer Substances 0.000 description 1
• 239000002953 phosphate buffered saline Substances 0.000 description 1
• 230000001766 physiological effect Effects 0.000 description 1
• 239000002504 physiological saline solution Substances 0.000 description 1
• 210000003635 pituitary gland Anatomy 0.000 description 1
• 229920000191 poly(N-vinyl pyrrolidone) Polymers 0.000 description 1
• 229920001583 poly(oxyethylated polyols) Polymers 0.000 description 1
• 229920001451 polypropylene glycol Polymers 0.000 description 1
• 229950008882 polysorbate Drugs 0.000 description 1
• 229920002451 polyvinyl alcohol Polymers 0.000 description 1
• 230000001323 posttranslational effect Effects 0.000 description 1
• 239000002244 precipitate Substances 0.000 description 1
• 230000002028 premature Effects 0.000 description 1
• 239000003755 preservative agent Substances 0.000 description 1
• 239000002987 primer (paints) Substances 0.000 description 1
• MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
• 229960004919 procaine Drugs 0.000 description 1
• 230000002947 procoagulating effect Effects 0.000 description 1
• 238000000159 protein binding assay Methods 0.000 description 1
• 238000001742 protein purification Methods 0.000 description 1
• 210000001938 protoplast Anatomy 0.000 description 1
• 239000002213 purine nucleotide Substances 0.000 description 1
• 150000003212 purines Chemical class 0.000 description 1
• 239000002719 pyrimidine nucleotide Substances 0.000 description 1
• 150000003230 pyrimidines Chemical class 0.000 description 1
• 238000003259 recombinant expression Methods 0.000 description 1
• 238000011084 recovery Methods 0.000 description 1
• 230000008929 regeneration Effects 0.000 description 1
• 238000011069 regeneration method Methods 0.000 description 1
• 230000003362 replicative effect Effects 0.000 description 1
• 239000011347 resin Substances 0.000 description 1
• 229920005989 resin Polymers 0.000 description 1
• 108091008146 restriction endonucleases Proteins 0.000 description 1
• 210000001995 reticulocyte Anatomy 0.000 description 1
• 238000010839 reverse transcription Methods 0.000 description 1
• 230000002441 reversible effect Effects 0.000 description 1
• 206010039073 rheumatoid arthritis Diseases 0.000 description 1
• 235000009566 rice Nutrition 0.000 description 1
• 102220283785 rs1344101243 Human genes 0.000 description 1
• 102220270545 rs1383831944 Human genes 0.000 description 1
• 102220278864 rs1554568431 Human genes 0.000 description 1
• 102220283290 rs1555591958 Human genes 0.000 description 1
• 102220289580 rs33916541 Human genes 0.000 description 1
• 102220118941 rs771216638 Human genes 0.000 description 1
• 210000000468 rubriblast Anatomy 0.000 description 1
• 230000007017 scission Effects 0.000 description 1
• 239000006152 selective media Substances 0.000 description 1
• 210000000717 sertoli cell Anatomy 0.000 description 1
• 230000009450 sialylation Effects 0.000 description 1
• 239000000741 silica gel Substances 0.000 description 1
• 229910002027 silica gel Inorganic materials 0.000 description 1
• 210000002027 skeletal muscle Anatomy 0.000 description 1
• 235000020183 skimmed milk Nutrition 0.000 description 1
• 239000004055 small Interfering RNA Substances 0.000 description 1
• 239000011734 sodium Substances 0.000 description 1
• 229910052708 sodium Inorganic materials 0.000 description 1
• 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
• 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
• HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
• 229940001584 sodium metabisulfite Drugs 0.000 description 1
• 235000010262 sodium metabisulphite Nutrition 0.000 description 1
• RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
• 239000007787 solid Substances 0.000 description 1
• 239000000600 sorbitol Substances 0.000 description 1
• 239000003549 soybean oil Substances 0.000 description 1
• 235000012424 soybean oil Nutrition 0.000 description 1
• 210000004989 spleen cell Anatomy 0.000 description 1
• 230000010473 stable expression Effects 0.000 description 1
• 239000008107 starch Substances 0.000 description 1
• 235000019698 starch Nutrition 0.000 description 1
• 210000000130 stem cell Anatomy 0.000 description 1
• 230000035882 stress Effects 0.000 description 1
• 239000007929 subcutaneous injection Substances 0.000 description 1
• 239000005720 sucrose Substances 0.000 description 1
• 238000004114 suspension culture Methods 0.000 description 1
• 230000002459 sustained effect Effects 0.000 description 1
• 238000013268 sustained release Methods 0.000 description 1
• 229920001059 synthetic polymer Polymers 0.000 description 1
• 239000000454 talc Substances 0.000 description 1
• 229910052623 talc Inorganic materials 0.000 description 1
• 230000008685 targeting Effects 0.000 description 1
• 229940126585 therapeutic drug Drugs 0.000 description 1
• 238000002560 therapeutic procedure Methods 0.000 description 1
• RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
• 229940033663 thimerosal Drugs 0.000 description 1
• 125000003396 thiol group Chemical group [H]S* 0.000 description 1
• 229960002175 thyroglobulin Drugs 0.000 description 1
• 239000003104 tissue culture media Substances 0.000 description 1
• 238000012090 tissue culture technique Methods 0.000 description 1
• 210000003371 toe Anatomy 0.000 description 1
• 230000005030 transcription termination Effects 0.000 description 1
• 238000001890 transfection Methods 0.000 description 1
• 230000009466 transformation Effects 0.000 description 1
• 230000009261 transgenic effect Effects 0.000 description 1
• 230000032258 transport Effects 0.000 description 1
• 230000000472 traumatic effect Effects 0.000 description 1
• 229920001733 tresyl monomethoxy PEG Polymers 0.000 description 1
• 150000003626 triacylglycerols Chemical class 0.000 description 1
• 206010044652 trigeminal neuralgia Diseases 0.000 description 1
• 239000013638 trimer Substances 0.000 description 1
• LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
• 239000002753 trypsin inhibitor Substances 0.000 description 1
• OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
• 241000701161 unidentified adenovirus Species 0.000 description 1
• 241001529453 unidentified herpesvirus Species 0.000 description 1
• 230000003827 upregulation Effects 0.000 description 1
• 229940035893 uracil Drugs 0.000 description 1
• DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 1
• 229940045145 uridine Drugs 0.000 description 1
• 230000002227 vasoactive effect Effects 0.000 description 1
• 230000025033 vasoconstriction Effects 0.000 description 1
• 230000024883 vasodilation Effects 0.000 description 1
• 235000013311 vegetables Nutrition 0.000 description 1
• 239000013603 viral vector Substances 0.000 description 1
• 238000001262 western blot Methods 0.000 description 1
• 150000003751 zinc Chemical class 0.000 description 1